Sandbox:khurram: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 8: | Line 8: | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases | ||
| colspan="5" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | | colspan="5" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | ||
| | | | ||
! colspan="9" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ! colspan="9" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
Line 16: | Line 15: | ||
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms''' | | colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms''' | ||
! colspan="2" rowspan="2" |Physical examination | ! colspan="2" rowspan="2" |Physical examination | ||
| | | | ||
|- | |- | ||
| | | | ||
! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
Line 31: | Line 28: | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness in extremities | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness in extremities | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Edema in extremities | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Edema in extremities | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Warmth in extremities | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet count | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet count | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT | ||
Line 48: | Line 44: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
Line 71: | Line 66: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 91: | Line 85: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 111: | Line 104: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 131: | Line 123: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 145: | Line 136: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Disseminated intravascular coagulation (DIC)<ref name="pmid25535423">{{cite journal |vauthors=Venugopal A |title=Disseminated intravascular coagulation |journal=Indian J Anaesth |volume=58 |issue=5 |pages=603–8 |date=September 2014 |pmid=25535423 |pmc=4260307 |doi=10.4103/0019-5049.144666 |url=}}</ref> | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Disseminated intravascular coagulation (DIC)<ref name="pmid25535423">{{cite journal |vauthors=Venugopal A |title=Disseminated intravascular coagulation |journal=Indian J Anaesth |volume=58 |issue=5 |pages=603–8 |date=September 2014 |pmid=25535423 |pmc=4260307 |doi=10.4103/0019-5049.144666 |url=}}</ref><ref name="pmid27276832">{{cite journal |vauthors=Makruasi N |title=Treatment of Disseminated Intravascular Coagulation |journal=J Med Assoc Thai |volume=98 Suppl 10 |issue= |pages=S45–51 |date=November 2015 |pmid=27276832 |doi= |url=}}</ref> | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |+ | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |+ | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |+/- | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |+ | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |+ | ||
| style="background: #F5F5F5; padding: 5px;" |+ | |||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" |Decreased | | style="background: #F5F5F5; padding: 5px;" |Decreased | ||
| style="background: #F5F5F5; padding: 5px;" |Increased | | style="background: #F5F5F5; padding: 5px;" |Increased | ||
Line 162: | Line 152: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |N/A | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Elevated fibrin degradation products (D-dimers) | * Elevated fibrin degradation products (D-dimers) | ||
Line 169: | Line 159: | ||
|- | |- | ||
|Antiphospholipid antibody syndrome | |Antiphospholipid antibody syndrome | ||
| | | | ||
| | | | ||
Line 189: | Line 178: | ||
|- | |- | ||
|Heparin induced thrombocytopenia (HIT) | |Heparin induced thrombocytopenia (HIT) | ||
| | | | ||
| | | |
Revision as of 18:59, 23 August 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Differentiating [disease name] from other diseases on the basis of [symptom 1], [symptom 2], and [symptom 3]
On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | ||||||||||||||||
Lab Findings | Imaging | Histopathology | |||||||||||||||
Symptoms of DVT | Symptoms of Pulmonary Embolism | Symptoms of Myocardial Infarction | Tenderness in extremities | Edema in extremities | Warmth in extremities | Platelet count | PT | aPTT | Peripheral blood smear | Bleeding time | Doppler ultrasound | Chest CT scan | Head CT with contrast | ||||
Antithrombin deficiency | - | - | - | - | - |
| |||||||||||
Factor V Leiden mutation | |||||||||||||||||
Protein C deficiency | |||||||||||||||||
Protein S deficiency | |||||||||||||||||
Prothrombin gene mutation | |||||||||||||||||
Disseminated intravascular coagulation (DIC)[1][2] | + | + | +/- | + | + | + | Decreased | Increased | Increased | Shistocytes | Increased | N/A |
| ||||
Antiphospholipid antibody syndrome | |||||||||||||||||
Heparin induced thrombocytopenia (HIT) |
References
- ↑ Venugopal A (September 2014). "Disseminated intravascular coagulation". Indian J Anaesth. 58 (5): 603–8. doi:10.4103/0019-5049.144666. PMC 4260307. PMID 25535423.
- ↑ Makruasi N (November 2015). "Treatment of Disseminated Intravascular Coagulation". J Med Assoc Thai. 98 Suppl 10: S45–51. PMID 27276832.